Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3195483

In Collections

This item can be found in the following collections:

Yasuma, R.; Cicatiello, V.; Mizutani, T.; Tudisco, L.; Kim, Y.; Tarallo, V.; ... ; Ambati, J. (2016)

Intravenous immune globulin suppresses angiogenesis in mice and humans

Article / Letter to editor
Human intravenous immune globulin (IVIg), a purified IgG fraction composed of similar to 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcyRI, a high-affinity receptor for IgG1. Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases, namely, neovascular age-related macular degeneration, corneal neovascularization, colorectal cancer, fibrosarcoma and peripheral arterial ischemic disease. Angioinhibition was mediated by the Fc region of IVIg, required FcyRl and had similar potency in transgenic mice expressing human FcyRs...Show moreHuman intravenous immune globulin (IVIg), a purified IgG fraction composed of similar to 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcyRI, a high-affinity receptor for IgG1. Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases, namely, neovascular age-related macular degeneration, corneal neovascularization, colorectal cancer, fibrosarcoma and peripheral arterial ischemic disease. Angioinhibition was mediated by the Fc region of IVIg, required FcyRl and had similar potency in transgenic mice expressing human FcyRs. Finally, IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities. These data place IVIg, an agent approved by the US Food and Drug Administration, as a novel angioinhibitory drug in doses that are currently administered in the clinical setting. In addition, they raise the possibility of an unintended effect of IVIg on blood vessels.Show less
All authors
Yasuma, R.; Cicatiello, V.; Mizutani, T.; Tudisco, L.; Kim, Y.; Tarallo, V.; Bogdanovich, S.; Hirano, Y.; Kerur, N.; Li, S.J.; Yasuma, T.; Fowler, B.J.; Wright, C.B.; Apicella, I.; Greco, A.; Brunetti, A.; Ambati, B.K.; Helmers, S.B.; Lundberg, I.E.; Viklicky, O.; Leusen, J.H.W.; Verbeek, J.S.; Gelfand, B.D.; Bastos-Carvalho, A.; Falco, S. de; Ambati, J.
Date
2016-01-01
Journal
Signal Transduction and Targeted Therapy
Volume
1
DOI
doi:10.1038/sigtrans.2015.2